Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842800 · ClinicalTrials.gov registry record · Early Phase 1
Characterizing Clinical and Pharmacological Neuroimaging Biomarkers
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 143
- Enrollment target
NCT03842800 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 143 participants.
The verdict
NCT03842800, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patients with schizophrenia.
Interventions
- DRUG Ketamine
- OTHER MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2018-08-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03842800
The ClinicalTrials.gov registry entry for NCT03842800 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT03842800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03842800 about?
NCT03842800 is a clinical study titled "Characterizing Clinical and Pharmacological Neuroimaging Biomarkers". This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patie...
What is the current status of trial NCT03842800?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 143 participants. The study started on 2013-04-01. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT03842800?
The interventions under investigation include: Ketamine (DRUG), MRI (OTHER).
Who is sponsoring clinical trial NCT03842800?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.